Summary & Overview
CPT 81233: BTK Gene Variant Detection, Technical Laboratory Test
CPT code 81233 represents a technical laboratory test for detecting common variants in the Bruton’s tyrosine kinase (BTK) gene. This molecular diagnostic code is used when a lab performs the analytic component of BTK testing, a clinically significant assay for conditions that affect B-cell development and immune function. Nationally, BTK testing informs diagnosis, prognostication, and targeted therapy decisions in hematology and immunology, making accurate coding important for clinical documentation and claims processing.
Key payers in the national landscape include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find context on the clinical purpose of the test, typical sites of service, and which payers commonly cover molecular diagnostic services. The analysis outlines benchmarks where available, summarizes relevant policy positions and prior authorization trends when reported by payers, and situates CPT code 81233 within broader molecular testing practice. The publication also highlights coding considerations for separating the technical component from other testing components and notes areas where payer coverage language often varies.
This summary is intended for clinicians, laboratory billing staff, and policy professionals seeking a concise reference on CPT code 81233, its clinical role, and payer coverage context at a national level.
Billing Code Overview
CPT code 81233 describes a laboratory technical procedure to detect common changes in the gene for Bruton’s tyrosine kinase (BTK). The service is a molecular diagnostic test focused on identifying known variants in the BTK gene that are relevant to inherited or acquired conditions affecting B-cell function.
Service type: Molecular diagnostic testing / clinical laboratory service
Typical site of service: Clinical laboratory or reference molecular diagnostics laboratory
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 58-year-old male with a history of chronic lymphocytic leukemia (CLL) is referred by his hematologist for molecular testing to detect common variants in the Bruton’s tyrosine kinase (BTK) gene. Peripheral blood is collected in an EDTA tube during an outpatient clinic visit. The specimen is labeled and sent to a molecular diagnostics laboratory. The laboratory technologist performs DNA extraction, then runs a validated targeted sequencing assay to detect common activating and resistance-associated BTK variants. Results are interpreted by a molecular pathologist and a report is issued to the ordering hematologist documenting detected variants, method, limitations, and clinical relevance for targeted therapy selection and resistance monitoring.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
26 | Professional component | Use when only the professional interpretation and report are billed separately from the technical lab work. |
TC | Technical component | Use when only the technical component of the test (laboratory processing and analysis) is billed. |